Another CMC “gotcha”—Intarcia receives CRL for Exenatide implant: http://www.prnewswire.com/news-releases/intarcia-provides-corporate-update-300527104.html The Company received clear and constructive guidance from the Agency regarding manufacturing aspects of the CRL and is on a clear path to move forward.Emphasis added. Intarcia has been a high-profile private biotech company, having raised $225M in 2015 (#msg-113238024).